SMN2 and proximal spinal muscular atrophy: The importance of SMN protein levels is further evidenced by the fact that the mechanism of action for both US Food and Drug Administration (FDA)-approved treatments currently available for SMA, Spinraza (nusinersen) and Zolgensma (onasemnogene abeparvovec), aim to increase SMN protein levels (Sumner and Crawford, 2018).